4-EA-NBOMe

4-EA-NBOMe is a psychedelic and hallucinogenic drug that belongs to the NBOMe series of substituted phenethylamines. It is also known as 4-Ethylamino-NBOMe or 4-EA-2C-B-NBOMe. This compound is a derivative of the 2C family of psychedelics, specifically 2C-B, which was first synthesized by Alexander Shulgin.

Chemistry

4-EA-NBOMe is a phenethylamine derivative and shares a similar chemical structure with other drugs in the NBOMe class. The NBOMe class of drugs is characterized by a 2-methoxybenzyl (NBOMe) group attached to the nitrogen (N) of the phenethylamine backbone. This NBOMe group significantly increases the potency of the compounds. The 4-EA-NBOMe molecule features an ethylamine chain attached to the 4-position of the phenyl ring.

Pharmacology

The exact pharmacology of 4-EA-NBOMe is not well understood. However, like other NBOMe compounds, it is believed to act as a highly potent partial agonist for the 5-HT2A receptor, which is involved in the regulation of mood, anxiety, schizophrenia, and consciousness. The drug's effects are believed to result from its activity at this receptor in the brain.

Effects

The effects of 4-EA-NBOMe are largely unknown due to the lack of scientific research. However, anecdotal reports suggest that it produces effects similar to other psychedelic drugs, including intense visual hallucinations, altered perception of time, and euphoria. It may also cause negative effects such as anxiety, paranoia, and potentially dangerous changes in heart rate and blood pressure.

Legal Status

The legal status of 4-EA-NBOMe varies by country. In many countries, including the United States, it is considered a controlled substance due to its potential for abuse and lack of accepted medical use.

See Also

• 25I-NBOMe
• 25C-NBOMe
• 25B-NBOMe
• 2C-B
• Psychedelic drug
• Hallucinogen
• Alexander Shulgin

References

‎